Products
Cann Group — Australia's Pioneering Medicinal Cannabis Company (2026)
Cann Group (ASX: CAN) was one of the first dual-licensed Australian medicinal cannabis companies. A complete profile of Cann Group's history, cultivation operations, product range and patient access pathway in 2026.
Cann Group Limited (ASX: CAN) holds a special place in Australia’s medicinal cannabis history: it was one of the first companies to receive both a cultivation licence and a research licence from the Office of Drug Control, making it a dual-licensed pioneer in the Australian industry. Founded in 2015 — even before the national medicinal cannabis legislation passed in 2016 — Cann Group has been at the forefront of Australian cannabis medicine from the very beginning.
Company history and significance
Founded: 2015, Melbourne, Victoria
ASX listing: ASX: CAN
Headquarters: Mildura, Victoria (cultivation facility)
Key achievement: Among first dual-licensed (cultivation + research) cannabis entities in Australia
Cultivation: State-of-the-art indoor facility in Mildura, Victoria
Cann Group was founded by entrepreneurs and medical professionals who recognised that Australia’s planned medicinal cannabis legislation would require domestic production infrastructure. The company navigated the complex early regulatory environment and emerged as one of the first entities legally cultivating cannabis in Australia under TGA/ODC oversight.
The Mildura facility — located in regional Victoria — represents one of Australia’s largest purpose-built medicinal cannabis cultivation and manufacturing operations. The site includes indoor cultivation rooms, extraction facilities, and quality control laboratories.
Cultivation and manufacturing
Cann Group’s Mildura facility produces cannabis under controlled conditions:
- Indoor controlled environment: Temperature, humidity, CO2 and light management
- GMP-certified manufacturing: Good Manufacturing Practice standards for pharmaceutical production
- Extraction capability: Cannabis oil extraction and formulation on-site
- Quality testing: Independent third-party testing for all products
The Victorian location provides access to skilled agricultural and pharmaceutical workers, regional water resources, and proximity to Melbourne’s biomedical research community.
Cann Group product range
Cann Group produces dried flower, oils and other cannabis formulations. Their products span:
- Dried cannabis flower: Multiple cultivars covering indica, sativa and hybrid categories
- Cannabis oil: THC-dominant, balanced THC:CBD, and CBD-dominant formulations
- Capsules: Standardised cannabinoid dosing in capsule format
- Specialist formulations: Including high-CBD products for patients seeking non-psychoactive cannabis therapy
Research and clinical engagement
One of the distinguishing features of Cann Group’s business model is its integration of research. The dual research licence allows Cann Group to conduct clinical investigations into cannabis medicine — contributing to Australia’s evidence base for medicinal cannabis.
Cann Group has been involved in or supported research exploring:
- Pain management outcomes with medicinal cannabis
- Sleep quality studies
- The therapeutic potential of specific cannabinoid:terpene combinations
This research orientation positions Cann Group as a contributor to the scientific evidence base, not just a commercial producer.
How to access Cann Group products
Cann Group products are available through the TGA SAS-B prescription framework:
- Consult a TGA-authorised prescriber (telehealth or in-person)
- Your prescriber specifies Cann Group products appropriate for your condition
- Prescription filled through registered Australian pharmacies
- National delivery or pharmacy collection
Cann Group’s products are distributed through major Australian cannabis pharmacy networks.
Cann Group’s position in 2026
Australia’s medicinal cannabis market has grown from a handful of licensed entities in 2017 to over 100 by 2026. In this competitive landscape, Cann Group’s early-mover advantage, domestic cultivation scale, research credentials, and established pharmacy relationships maintain its position as one of the industry’s foundational companies.
Frequently asked questions — Cann Group
Is Cann Group publicly listed?
Yes — Cann Group Limited trades on the Australian Securities Exchange (ASX: CAN) and publishes regular financial reports.
Where is Cann Group based?
Operations are primarily at the Mildura, Victoria cultivation and manufacturing facility. Corporate offices are in Melbourne, Victoria.
What makes Cann Group different from other Australian producers?
Its early-mover position, dual cultivation and research licensing, and Mildura facility scale. The research focus also differentiates it — Cann Group contributes to clinical evidence as well as producing commercial products.
Can I request Cann Group products from my prescriber?
Yes. Discuss your preferences with your prescriber — many are familiar with Cann Group’s product range and can request specific Cann Group products in your TGA SAS-B application.